Eyepoint pharmaceuticals, inc. (EYPT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10
Cash flows from operating activities:
Net loss

-50,729

-56,793

-57,977

-75,456

-98,386

-86,126

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-23,776

-

-20,306

-20,263

-19,152

6,347

7,526

10,337

10,898

-13,355

-13,335

-13,942

-13,036

-11,900

-10,215

-10,107

-24,959

-24,835

-22,713

-22,712

-7,947

-8,628

0

0

0

Adjustments to reconcile net loss to cash flows used in operating activities:
Amortization of intangible assets

2,460

2,460

2,459

2,459

2,459

1,844

1,414

981

548

727

723

724

729

737

747

756

760

763

766

770

775

781

782

778

773

769

768

769

771

771

1,397

2,037

2,684

3,321

3,324

3,302

0

0

0

Depreciation of property and equipment

133

144

163

175

182

181

171

167

158

142

124

91

123

125

129

152

121

114

106

112

115

128

135

139

160

182

209

225

246

233

221

190

127

98

67

53

0

0

0

Amortization of debt discount

627

596

588

582

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivatives

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

170

180

514

844

1,140

0

0

0

Amortization of bond (discount) premium on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-9

-8

12

48

87

118

125

114

98

85

62

46

45

55

91

125

152

164

188

223

264

308

284

245

189

0

0

0

Non-cash interest expense

1,263

1,052

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

0

-3,810

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation

4,490

4,568

4,864

5,284

4,762

3,967

3,420

2,704

2,412

2,613

2,403

2,456

2,388

2,405

2,492

2,163

2,170

2,123

2,057

1,961

1,788

1,615

1,503

1,411

1,362

1,233

1,191

1,317

1,308

1,375

1,277

1,411

1,600

1,795

2,078

2,052

0

0

0

Change in fair value of derivative liability

-

-

-

-

-

-45,164

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable and other current assets

15,578

15,304

10,863

11,392

2,749

952

825

167

-76

-238

-241

-120

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

-

-

-

Inventory

2,473

1,859

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

59

4,596

2,521

3,622

5,182

2,455

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets and operating lease liabilities

8

46

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

30

-15

0

0

-240

-475

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Deferred revenue

-

-

-

-

-

-

-10

-

0

0

-129

-

0

0

103

-

-16

-42

-67

-94

-80

-1,186

-642

-267

-393

911

225

35

-57

-310

-315

-1,895

-2,258

-2,190

-1,030

880

0

0

0

Deferred rent

-

-

-

-

-

213

22

-20

-17

-15

-11

-9

-5

-2

1

5

7

12

15

18

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-18,309

-

-14,975

-14,627

9,798

10,297

10,518

12,620

-10,888

-10,671

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-59,710

-56,699

-56,033

-53,027

-42,002

-33,487

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-5,918

-5,388

-3,611

-3,170

0

0

0

Cash flows from investing activities:
Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

5,052

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

12,506

-

0

0

0

-

-

-

-

7,758

10,912

13,062

14,460

15,392

17,268

16,850

16,228

15,963

0

0

0

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5,400

-

2,900

750

2,150

3,350

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of marketable securities

-

-

-

-

-

-

-

-

-

-

-

18,743

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

15,538

12,447

9,698

6,598

0

0

0

Acquisition of Icon Bioscience Inc., net of cash acquired

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

47

213

230

339

359

176

153

108

189

206

211

147

67

82

102

113

157

169

166

161

244

255

246

248

94

53

72

68

55

61

188

405

464

454

345

133

0

0

0

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

33

33

33

33

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

1,564

-

-26

-4,242

-7,272

-6,733

-6,269

-5,750

-1,383

66

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-47

-213

-230

-339

-2,066

-16,956

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-1,091

-3,754

-6,875

-9,498

0

0

0

Cash flows from financing activities:
Proceeds from exercise of warrants

-

-

-

-

-

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of stock, net of issuance costs

0

-

-

-

-

-

40,552

41,515

22,409

15,448

9,367

8,404

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of long-term debt

-

50,000

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of debt issue costs

-

1,341

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of long-term debt principal

-

20,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment of extinguishment of debt costs

-

2,716

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net settlement of stock units to satisfy statutory tax withholding

119

120

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options and employee stock purchase plan

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal payments on finance lease obligations

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of stock, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

18,149

11,144

9,915

4,669

0

0

0

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

99

231

161

490

490

358

338

188

235

0

0

0

-

-

-

-

-

-

-

-

114

0

0

0

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

0

0

16,990

-

16,868

338

188

235

221

7,678

9,119

19,044

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

42,676

33,864

32,260

58,752

71,104

82,831

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

Effect of foreign exchange rate changes on cash and cash equivalents

1

1

-1

-1

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents and restricted cash

-17,080

-23,047

-24,004

5,385

27,033

32,385

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of foreign exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-25

-

-7

-10

-10

-12

-18

-16

-10

-4

-3

-7

-9

-8

-11

0

-1

-6

-5

-1

-3

6

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

0

0

220

-

1,860

-18,541

2,704

3,787

4,452

14,532

-3,162

8,435

10,557

5,810

6,158

2,274

1,623

1,001

-1,423

-8,287

-6,921

1,031

-315

-2,602

0

0

0

Supplemental cash flow information:
Cash interest paid

5,049

4,870

4,232

2,416

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

56

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Stock issuance costs

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock issuance costs

0

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Debt issue costs

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued acquisition costs

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued development milestone

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued term loan exit fee

-

3,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Principal portion of finance lease liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of second tranche purchase liability

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of warrants issued with debt

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-